Yingli Phar­ma brings small mol­e­cule re­search to the US in new pact with MD An­der­son; UCB's pso­ri­at­ic arthri­tis drug shows pos­i­tive PhI­II re­sults

Shang­hai biotech Yingli Phar­ma wants to bring its small mol­e­cule drug re­search glob­al — and a new pact with MD An­der­son will help it get there.

Yingli and MD An­der­son have inked a 5-year col­lab­o­ra­tion deal that will put its can­cer can­di­dates — some of which have al­ready gen­er­at­ed da­ta in Chi­na — in­to tri­als in the US. The lead pro­gram is lin­perlis­ib, a PI3Kδ in­hibitor that’s in a Phase III tri­al in fol­lic­u­lar lym­phoma, ac­cord­ing to Yingli’s web­site. In the US, MD An­der­son will work with Yingli to put the can­di­date in a Phase II tri­al for pe­riph­er­al T cell lym­phoma (PT­CL), an un­com­mon and ag­gres­sive type of non-Hodgkin’s lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.